ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
1.120
-0.110 (-8.94%)
At close: Feb 21, 2025, 4:00 PM
1.200
+0.080 (7.14%)
After-hours: Feb 21, 2025, 7:59 PM EST
ReShape Lifesciences Employees
ReShape Lifesciences had 29 employees as of December 31, 2023. The number of employees decreased by 11 or -27.50% compared to the previous year.
Employees
29
Change (1Y)
-11
Growth (1Y)
-27.50%
Revenue / Employee
$282,172
Profits / Employee
-$243,690
Market Cap
798.20K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RSLS News
- 6 days ago - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering - GlobeNewsWire
- 19 days ago - ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 5 weeks ago - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys - GlobeNewsWire
- 3 months ago - ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - GlobeNewsWire
- 3 months ago - ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 3 months ago - ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology - GlobeNewsWire
- 5 months ago - ReShape Lifesciences Announces 1-for-58 Reverse Stock Split - GlobeNewsWire